Overview

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Collaborator:
Endo Pharmaceuticals